01069 CN HEALTH TECH
- 0.037
- +0.001+2.78%
CN HEALTH TECH News
China Health Technology Group Holding's (HKG:1069) Profits May Be Overstating Its True Earnings Potential
CN HEALTH TECH: Annual Report 2024
China Health Technology Turns to Profit in FY2024
cn health tech group (01069.HK) turned losses into profits, reaching 0.2 billion yuan for the year.
Gelonghui September 30th. cn health tech (01069.HK) announced that the income for the year ended June 30, 2024 was approximately RMB 47.6 million. The attributable profits of the group amounted to approximately RMB 0.2 billion (for the year ended June 30, 2023: a loss of approximately RMB 10.8 million). Basic earnings per share were 29.79 RMB; no dividends are recommended for the 2024 fiscal year. Revenue generated by the group's forestry management business mainly comes from selling logs harvested from the group's forests. Revenue from log sales is recognized when control of the relevant goods is transferred to the customer.
Express News | China Health Technology- Profit Attributable for FY2024 RMB200.0 Mln
CN HEALTH TECH: ANNOUNCEMENT OF FINANCIAL RESULTSFOR THE YEAR ENDED 30 JUNE 2024
China Health Technology Group [01069] is now reported at 0.063 Hong Kong dollars, with an increase of 12.50%.
As of 10:13, China Health Technology Group [01069] reported 0.063 Hong Kong dollars, up 0.007 Hong Kong dollars or 12.50% from the previous closing price of 0.056 Hong Kong dollars, with a trading volume of 0.003 million Hong Kong dollars. The highest price today is 0.063 Hong Kong dollars, and the lowest price is 0.062 Hong Kong dollars. Based on the closing price from yesterday, the 10-day average price is 0.08 Hong Kong dollars, and the 50-day average price is 0.06 Hong Kong dollars. The current PE ratio is -0.62 times, and the 14-day relative strength index is 56.48.
China Health Technology Group (01069.HK) plans to hold a board of directors meeting on September 30th to approve the annual performance.
China Health Technology Group (01069.HK) announced on September 17th that the board of directors will hold a meeting on September 30th, 2024 (Monday) to review and approve the group's annual performance announcement for the fiscal year ending June 30, 2024, and consider the payment of final dividends (if any).
Express News | China Bozza Development - to Place up to 143 Mln Shares at HK$0.043 per Placing Share
China Health Technology Group Share Placement Lapses
China Health Technology Group (01069.HK): New share issuance under general authorization is invalidated.
China Health-Tech Group (01069.HK) announced on July 8th that the conditions under the placement agreement were not met before July 5th, 2024. Therefore, the placement agreement did not become unconditional and expired on July 5th, 2024. Pursuant to the placement agreement, all obligations and responsibilities of the counterparties in relation to the placement matter will be terminated, and except for any prior breach, no counterparty shall make any claim against any other party in respect of any matter arising out of or in connection with the placement matter.
China Health Technology Hires Auditor
China Health Technology Group Limited (01069.HK) appoints Zhongzhi Xin (Hong Kong) as its new auditor.
China Health Technology Group (01069.HK) announced on June 14 that the board of directors has appointed Zhongzhi Xing (Hong Kong) Certified Public Accountants Limited ("Zhongzhi Xing (Hong Kong)") as the company's new auditor.
China Health Technology to Place 143 Million Shares for HK$9 Million
China Health Technology Group (01069) plans to sell a total of up to 143 million shares at a discount of about 13.70% to raise about HK$8.6 million
China Health Technology Group (01069) issued an announcement. On May 28, 2024 (after the trading period), the company...
China Health Technology Group (01069) and Scura signed a strategic cooperation memorandum to jointly develop the R&D and sales business of ginseng extracted ion energy water in China
China Health Technology Group (01069) announced that on May 16, 2024, the company and Fujian Ningdes...
Statutory Earnings May Not Be The Best Way To Understand China Health Technology Group Holding's (HKG:1069) True Position
China Health Technology Group Terminates 52% Stake Acquisition Deal
China Health Technology Group (01069.HK) terminated the acquisition of 52% shares in Liuba Jiashisen Traditional Chinese Medicine Comprehensive Development
Gelonghui, April 8, 丨 China Health Technology Group (01069.HK) announced the acquisition of 52% of the shares in Liuba Jiashisen Traditional Chinese Medicine Comprehensive Development. After signing the share sale agreement, the company then carried out detailed due diligence and other work on the seller. However, at the company's request, the seller failed to provide satisfactory due diligence documentation to the company. Following friendly negotiations between the company and the seller, the contracting parties decided to terminate the acquisition. The Board believes that terminating the agreement will not have any significant adverse impact on the Group's business, operations, or financial position.
CN HEALTH TECH: Interim Report 2023
Analysis
Price Target
No Data
No Data